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Abstract  
αvβ6 integrin is upregulated in numerous carcinomas, where expression commonly 
correlates with poor prognosis. αvβ6 promotes tumour invasion, partly through 
regulation of proteases and cell migration, and is also the principal mechanism by which 
epithelial cells activate TGF-β1; this latter function complicates therapeutic targeting of 
αvβ6, since TGF-β1 has both tumour-promoting and -suppressive effects. It is unclear 
how these different αvβ6 functions are linked; both require actin cytoskeletal 
reorganisation, and it is suggested that tractive forces generated during cell migration 
activate TGF-β1 by exerting mechanical tension on the ECM-bound latent complex. We 
examined the functional relationship between cell invasion and TGF-β1 activation in 
pancreatic ductal adenocarcinoma (PDAC) cells, and confirmed that both processes are 
αvβ6-dependent. Surprisingly, we found that cellular functions could be biased towards 
either motility or TGF-β1 activation depending on the presence or absence of epidermal 
growth factor receptor pathway substrate 8 (Eps8), a regulator of actin remodelling, 
endocytosis and GTPase activation. Similar to αvβ6, we found that Eps8 was 
upregulated in >70% of PDAC. In complex with Abi1/Sos1, Eps8 regulated αvβ6-
dependent cell migration through activation of Rac1. Downregulation of Eps8, Sos1 or 
Rac1 suppressed cell movement, while simultaneously increasing αvβ6-dependent 
TGF-β1 activation. This latter effect was modulated through increased cell tension, 
regulated by Rho activation. Thus, the Eps8/Abi1/Sos1 tricomplex acts as a key 
molecular switch altering the balance between Rac1 and Rho activation; its presence or 
absence in PDAC cells modulates αvβ6-dependent functions, resulting in a pro-
migratory (Rac1-dependent) or a pro-TGF-β1 activation (Rho-dependent) functional 
phenotype respectively. 




The epithelial-specific integrin αvβ6 is not expressed in healthy tissue but is 
upregulated during epithelial remodelling, where it interacts with several ligands 
including fibronectin, tenascin, vitronectin and the latency-associated peptide of TGF-β1 
(LAP) and TGF-β3 [1-3]. αvβ6 is upregulated in numerous carcinomas, including 
pancreatic ductal adenocarcinoma (PDAC; [4-7]), and a high level of expression is 
prognostic in several tumour types, including colorectal, lung and breast carcinomas [6, 
8-9]. Consistent with this, αvβ6 promotes tumour cell invasion and metastasis, partly by 
regulating multiple proteases (MMP-9, MMP-2, MMP-13 and uPA; [5, 10]). αvβ6 is also 
the principal epithelial activator of TGF-β1 [3, 11], interacting with its latency-associated 
peptide to induce a conformational change in the latent complex to expose the active 
cytokine [12,13]. The potential for the therapeutic targeting of αvβ6 is complicated by its 
role in TGF-β1 activation, while TGF-β1 has numerous well-described pro-tumorigenic 
effects, including promoting tumour cell epithelial-to-mesenchymal transition (EMT [6]), 
immune suppression and stromal myofibroblast differentiation [14], its role as a tumour 
suppressor in the stages of early carcinogenesis has raised the possibility that targeting 
the integrin in the wrong setting might act to promote, rather than suppress tumour 
progression. Notably, inhibiting αvβ6 in a transgenic model of PDAC has been shown 
previously to promote early and late disease stages in the presence of wild-type SMAD4 
[15]. 
 
Several studies have emphasised the importance of cell-mediated mechanical force 
application in αvβ6-dependent activation of TGF-β1, whereby actomyosin-dependent 
tractive and tensile forces are applied, via αvβ6, to ECM-associated LAP [3, 11-13]. 
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Reorganisation of the actin cytoskeleton is integral to cell migration, with tension 
transmitted to the ECM through integrin-containing adhesion complexes at the cell 
surface; this is mediated through Rho GTP-ases (Rho, Rac and Cdc42 [16]). Notably, 
epidermal growth factor receptor pathway substrate 8 (Eps8) has been shown to control 
actin remodelling both directly through actin capping and bundling, and indirectly 
through activation of Rac1 [17-19]. Its multiple binding partners, including actin, Abi1, 
Sos1, RN-Tre, IRSp53, palladin, F-actin and certain integrin β subunits (β1, β3, β5), 
indicate that Eps8 sits at the heart of a complex system regulating actin reorganisation 
[17-21]. Moreover, Eps8 upregulation in several cancers, including PDAC, has been 
shown to promote a pro-migratory phenotype [22-25].  
 
In this study we examined the relationship between αvβ6-dependent cell invasion 
and TGF-β1 activation. Using PDAC (a cancer type with high levels of αvβ6 expression) 
as a model we confirmed that both processes are primarily regulated by αvβ6. 
Surprisingly, we found that motility and TGF-β1 activation have an inverse relationship, 
and that function can be biased towards either process depending on the presence or 
absence of Eps8, respectively. We found that Eps8, when in complex with Abi1/Sos1, 
promotes Rac1 activation, increasing cell migration and invasion; targeted siRNA 
knockdown of Eps8, Sos1 or Rac1 suppressed cell movement, but conversely, 
increased αvβ6-dependent activation of TGF-β1. This latter effect resulted from 
increased mechanical force application, and was driven by Rho activation. The loss of 
motility following Rac1 or Eps8 knockdown was restored if Rho was also inhibited. Thus 
the Eps8/Abi1/Sos1 tricomplex is a key regulator of αvβ6-dependent tumour cell function, 
acting as a molecular switch that alters the balance between Rac1 and Rho activation, 
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and biasing function towards a pro-migratory (Rac1-dependent) or pro-TGF-β1 
activation (Rho-dependent) phenotype respectively.  
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Materials and methods  
 
Antibodies and reagents 
Antibodies and siRNA sequences used are summarised in supplementary material, 
Table S1 [26] and Table S2.  
 
Cell lines and culture 
Capan1 and SU86.86 cells were cultured in DMEM, BxPC3 and SW1990 cells in RPMI, 
Panc0403 in RPMI supplemented with 10 mM HEPES buffer, 1 mM sodium pyruvate 
and 0.2 U/ml Insulin from bovine pancreas. Media contained 10% foetal bovine serum 
and 2 mM L-glutamine. The absence of Mycoplasma was regularly confirmed using PCR. 
DNA fingerprinting of PDAC cell lines (Capan1, BxPC3 and Panc0403) was performed 
using the GenomeLab Human STR Primer Set (Beckman-Coulter Inc, Brea, CA, USA) 
and results verified against the COSMIC cell line database, Wellcome Trust Sanger 
Institute. Primary pancreatic stellate cells (PPSC) were obtained using normal 
pancreatic tissue from two patients undergoing pancreatic resection at University 
Hospital Southampton (UHS). Appropriate ethical approval and patient consent was in 
place (REC no. 10/H0502/72).  
 
RNA Interference 
Cells were transfected with pre-designed, validated and optimised siRNA 
oligonucleotides (supplementary material, Table S2 and Figure S1) using 
Oligofectamine™ transfection reagent according to the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA, USA). Functional assays were performed at 24 (Organotypic 
assays) or 48 h (Transwell® / TGF-β activation) post-transfection.  
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Transwell® migration and invasion assays 
Motility assays were performed using Transwell® migration inserts (8 µm pore size, 
polycarbonate membrane, Corning® Costar® Wiesbaden, Germany) as described 
previously [10]. For migration assays the underside of the inserts were coated with 0.5 
µg/ml latency-associated peptide of TGF-β1 (LAP); for invasion assays the top of each 
insert was coated with Matrigel (BD Biosciences, San Diego, CA, USA) diluted 1:1 with 
DMEM. Cells migrating/invading to the lower chamber were counted after overnight 




Organotypic cultures were prepared as described previously and contained 2.5 x 105 
HFFF2/PPSC cells [27]. 2.5 x 105 HFFF2/PPSC cells combined with 5 x 105 PDAC cells 
were seeded on top of the gels. Medium was changed every 2 days, and gels bisected, 
fixed and processed to paraffin wax on day 12. Cell invasion was quantified using 
ImageJ software.  
 
Immunohistochemistry of tissue microarrays (TMAs)  
TMAs were constructed from archival paraffin-embedded material at UHS. Pancreatic 
resection specimens were derived from 75 patients undergoing pancreatic resection for 
PDAC between 2005-2010. H&E stained slides were reviewed and triplicate 1mm 
cylindrical cores selected from representative areas of each tumour block and arrayed 
onto a new recipient paraffin block using a tissue arrayer (Alphelys Minicore® 3, Plaisir, 
France). Appropriate ethical and institutional ethical approval was obtained (REC no. 
10/H0502/72). Tissue staining was scored using the QuickScore method as 




Cells were lysed in NP40 lysis buffer (40 mM Tris-HCl pH 7.4, 1% NP40, 5 mM EDTA, 5 
mM EGTA, 50 mM NaCl, 5 mM NaF and protease inhibitor cocktail). Lysates containing 
equal amounts of protein were electrophoresed in 6-15% SDS-PAGE gels and 
electroblotted to PVDF membranes (Merck Millipore, Watford, UK) as described 
previously [29]. Antibodies used throughout the study are listed in supplementary 
material, Table S1 [26]. 
 
Modulation and determination of Rac1 activity 
Rac1 activation assays were performed as described previously [30]. 8 x 105 cells were 
plated 24 h post-transfection and allowed to settle for 6 h. Cells serum-starved overnight 
were lysed on ice following 5 min stimulation with EGF (20 ng/ml). Cleared cell lysates 
were incubated with GST-PAK-CRIB beads for 1 h at 4 °C. Active/Total Rac1 levels 
were analysed by Western Blotting.  
 
Transfection with constitutively active EGFP-tagged Rac1 (Rac1V12-GFP (J Monypenny, 
GKT, London, UK)) or vector control (pEGFP-C2; Invitrogen) was performed using 
Fugene HD transfection reagents (Promega, Madison, WI, USA) following the 
manufacturer’s protocol.  
 
Determination of Rho activity 
Active/Total RhoA levels were measured in 2 x 106 cells 48 h post-transfection using the 
Rho G-LISA activation assay kit and the Total RhoA ELISA kit (Cytoskeleton, Denver, 
CO, USA) following the manufacturer’s protocol. 
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Phalloidin staining of PDAC cells   
PDAC cells (4 x 105, 24 h post-transfection) were plated on 13-mm LAP-coated 
coverslips and serum-starved overnight. Immunofluorescence staining was performed 
using the Actin cytoskeleton staining kit (Merck Milllipore) according to the 
manufacturer’s instructions. Scoring of actin stress-fibre formation was performed in 
randomly selected, fully spread cells, in a minimum of 10 fields per condition. Mean 
fluorescence intensity (arbitrary units) was calculated using ImageJ.  
 
Traction force microscopy 
Ultrathin polyacrylamide hydrogels, embedded with FluoSpheres® carboxylate-modified  
0.2 µm fluorescent (505/515) microspheres (Thermo Fisher Scientific, Waltham, MA, 
USA), were generated as described previously [31-33] with some modifications. Briefly, 
NaOH-washed 14 mm glass-bottomed dishes (MatTek, Ashland, MA, USA) were amino-
silanated with 0.5% 3-aminopropyltrimethyoxysilane and incubated with glutaraldehyde 
for 30 mins. 20 µl FluoSpheres® suspension was added to 500 µl of 3% or 9% 
acrylamide/bis-acrylamide (37.5:1) solutions. 6 µl polyacrylamide FluoSpheres® 
suspension was immediately added to amino-silanated surfaces, overlaid with acid-
washed 13 mm coverslips and allowed to polymerise, to produce hydrogels with 
predicted elastic moduli of 400 Pa and 12.5 kPa. Hydrogels were treated with 0.2 mg/ml 
sulfo-SANPAH (Thermo Fisher Scientific), photoactivated with 365 nm UV light, washed 
with 50 mM HEPES (pH8.5) and coated with 0.5 µg/ml LAP. 
Cells were plated on LAP-coated hydrogels for >14 h, prior to imaging on a 3i Marianas 
spinning-disk confocal microscope. For each condition, multipoint brightfield and 488 nm 
image stacks (>12 µm) were acquired for each position. After imaging, cells were lysed 
with 1% SDS and multipoint positions reimaged to obtain unstrained bead positions.   
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Image analysis was performed using Fiji software on z-position-aligned pre- and post-
lysis stacks. Force-induced bead displacement and gel deformation was measured by 
Particle Image Velocitometry (PIV) using the iterative PIV(Advanced) plugin [31] by 3 
pass interrogation (3rd pass parameters: PIV3 interrogation window size = 40 px, SW3 
search window size = 80 px, VS3 vector spacing = 20 px). Traction forces and vectors 
were calculated by Fourier Transform Traction Cytometry (FTTC) using the FTTC plugin, 
predicted gel elastic moduli and a Poisson ratio of 0.5  [31]. 
 
Co-culture experiments 
HFFF2 cells were plated in an 8-well Permanox-coated chamber slide (Thermo Fisher 
Scientific, Waltham, MA, USA) at a density of 104 cells/well. After 48 h, 104 cancer 
cells/well were plated on top of the fibroblasts. After 72 h cells were fixed with 4% 
formaldehyde. Stress-fibres were visualised with αSMA (Dako, Ely, UK), cancer cells 
with cytokeratin (Dako) antibody using a Zeiss Axiovert 200 fluorescence microscope (at 
40X magnification using an Orca-ER digital camera (Hamamatsu)). αSMA Mean 
Fluorescence Intensity (arbitrary units) was calculated using ImageJ Software. 
 
TGF-β activation assay 
TGF-β1 activation was measured by co-culture of mink lung epithelial cells (MLEC) 
stably expressing a TGF-β1-responsive luciferase reporter construct (5 x 104 cells/well) 
with PDAC cells (12 x 104 cells/well) in serum-free conditions [29].  
 
Statistical analysis 
For functional assays, differences between experimental groups were examined with 
Student’s t-tests (Prism 4, GraphPad software). Statistical significance was indicated in 
the following way: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  Bars indicate the 
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standard deviation (SD) unless otherwise stated. Differences between 





αvβ6 is over-expressed in PDAC and promotes tumour invasion & TGF-β1 
activation 
αvβ6 expression has been reported to be upregulated in PDAC [7]. Our analysis of 75 
tumours similarly showed significantly increased αvβ6 expression in PDAC tissue (75% 
moderate/strong expression) compared with surrounding tissue (24% moderate/strong 
expression) (Figure 1A). Five PDAC cell lines were screened for expression of the αv 
and β6 integrin subunits; three (Capan1, BxPC3 and Panc0403) showed high 
expression of both subunits (Figure 1B; supplementary material, Figure S2A) and were 
chosen for use in functional assays. All three cell lines showed αvβ6-dependent 
migration and invasion, which was suppressed by an inhibitory αvβ6 antibody, 63G9 
(Figures 1C-D; supplementary material, Figure S2B). We next performed TGF-β1 
activation assays and found that only cell lines with high αvβ6 expression showed robust 
activation of the cytokine; this was significantly reduced following αvβ6 blockade (Figure 
1E; supplementary material, Figure S3). We then examined the role of αvβ6 in 
promoting collective tumour invasion in a 3D organotypic model using either human 
foetal foreskin fibroblasts (HFFF2) or primary pancreatic stellate cells (PPSC) as the 
stromal component. BxPC3 and Panc0403 cells invaded well in the presence of either 
stromal cell type, with invasion significantly inhibited following β6 siRNA knockdown 
(Figure 1F). Capan1 cells do not invade in this model.  These collective results confirm a 
central role for αvβ6 in tumour cell motility and TGF-β1 activation in pancreatic cancer.  
 
Eps8 is overexpressed in PDAC, promotes αvβ6-dependent PDAC motility but 
suppresses αvβ6-dependent TGF-β1 activation 
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Similar to αvβ6, Eps8 has also been reported to be upregulated in several carcinomas 
[22-23, 25, 30]. We examined Eps8 expression in the cohort of 75 patients and found 
significant upregulation in PDAC tissue (72%) compared with surrounding pancreatic 
tissue (26%) (Figure 2A). Of the five PDAC cell lines examined, the three αvβ6-positive 
lines expressed high levels of Eps8 (Figure 2B). We next investigated the role of Eps8 in 
αvβ6-dependent migration, invasion and TGF-β activation. We found that Eps8 siRNA 
knockdown significantly inhibited both αvβ6-dependent migration (Figure 2C; 
supplementary material, Figure S4A) and invasion (Figure 2D), whereas overexpression 
of Eps8-EGFP induced cell motility (supplementary material, Figure S5A). Unexpectedly, 
down-regulation of Eps8 induced, rather than inhibited, αvβ6-dependent TGF-β1 
activation (Figure 2E; supplementary material, Figure S4B). Consistent with this, 
overexpression of Eps8-EGFP suppressed activation of the cytokine (supplementary 
material, Figure S5B-C). These data suggest that αvβ6 regulates both PDAC motility 
and TGF-β1 activation, and that the presence of Eps8 shifts the balance of these 
functions towards motility.  
 
Eps8 mediates αvβ6-dependent functions via Rac1 activation 
Eps8 siRNA knockdown had no effect on αvβ6 levels/activation or cell adhesion 
(supplementary material, Figure S6) suggesting that Eps8-dependent TGF-β1 activation 
was not due to altered αvβ6 bioavailability or function. Eps8 modulates the cytoskeleton 
via its actin-binding and -capping activity, and through regulation of signalling pathways, 
including activation of the Rho GTPase, Rac1, when part of a tricomplex with Abi1 and 
Sos1 [20]. To determine whether Eps8 promotes Rac1 activation in PDAC cells, we 
performed Rac1 pull-down assays using epidermal growth factor (EGF); a stimulus that 
amplifies αvβ6-specific motility and Rac1 activation in these cell lines (supplementary 
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material, Figure S7). Eps8 knockdown suppressed EGF-dependent Rac1 activation 
(Figure 3A), which was similarly inhibited by knockdown of β6 (supplementary material, 
Figure S7C). Further investigation suggested involvement of the Eps8/Abi1/Sos1 
tricomplex; we found upregulated expression of the Rac1 guanine nucleotide exchange 
factor, Sos1, in PDAC tissue and cell lines (supplementary material, Figure S8A-B), and 
Sos1 siRNA knockdown suppressed EGF-induced Rac1 activation (supplementary 
material, Figure S8C). In motility assays, inhibition of Rac1 (siRNA, Figure 3B; Rac 
inhibitor NSC23766 (Merck Millipore), supplementary material, Figure S9A) significantly 
inhibited migration, and this was restored by expression of constitutively active Rac1V12 
(Figure 3C).  Inhibition of Sos1 also suppressed migration (siRNA, supplementary 
material, Figure S8D). Double knockdown of Eps8 and Rac1 did not produce a greater 
level of inhibition than that of the individual proteins (supplementary material, Figure 
S9B), suggesting that they function in the same pathway. PDAC cell invasion was also 
Rac1 and Sos1 dependent (Figure 3D; supplementary material, Figure S8E). 
Next, we examined the role of the Rac pathway in TGF-β1 activation. Inhibition of Rac1 
(siRNA, Figure 3E; NSC23766, supplementary material, Figure S9C) or Sos1 (siRNA, 
supplementary material, Figure S8F) resulted in a significant increase in αvβ6-
dependent TGF-β1 activation. Similar to migration assays, double knockdown of Eps8 
and Rac1 did not result in an additive effect (supplementary material, Figure S9D). 
These results provide evidence that Eps8, its binding partner Sos1, and their 
downstream effector Rac1 all promote αvβ6-dependent PDAC motility, yet inhibit αvβ6-
dependent TGF-β1 activation.  
 
Eps8 suppresses stress-fibre formation and cell traction   
αvβ6-mediated TGF-β1 activation is thought to require application of actomyosin-
dependent force on LAP to induce a conformational change in the TGF-β1 latent 
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complex [3, 11-13]. Initially, we examined intracellular stress-fibre formation as a 
surrogate measure of cytoskeletal tension. Eps8 or Rac1 knockdown led to a significant 
increase in stress-fibre formation measured by mean fluorescence intensity of Phalloidin 
staining (Figure 4A; supplementary material, Figure S10). We next examined whether 
Eps8 modulates tractive force using traction force microscopy to quantify cell-mediated 
force applied to LAP substrates of differing rigidities. siRNA-mediated knockdown of 
Eps8 in BxPC3 cells substantially increased the tractive forces irrespective of substrate 
rigidity (Figure 4B). Together, these data suggest that Eps8-dependent Rac1 activation 
inhibits TGF-β1 activation through suppressing the force applied to the latent TGF-β1 
complex.  
 
Eps8 suppression promotes Rho activation and function   
The role of Rho kinases in αvβ6-dependent TGF-β activation has previously been 
described [11, 34-35], and Rac1 signalling has been shown to antagonise Rho activity 
directly [36-37]. We therefore hypothesised that Eps8/Rac1 suppression may promote 
RhoA activation, promoting increased cell tension. RhoA activation assays confirmed an 
increase in activation following downregulation of Eps8 (Figure 5A). To further examine 
the functional relationship between Rac1 and Rho signalling, we performed migration 
(Figures 5B-C) and invasion assays (Figures 5D-E) using the specific cell-permeable 
exoenzyme C3 transferase-based selective Rho inhibitor (CT04; Cytoskeleton) following 
siRNA knockdown of Eps8 or Rac1. Treatment of Eps8-knockdown cells with this 
inhibitor lead to reduced stress-fibre formation, a readout of Rho activation, 
(supplementary material, Figure S11). We also found that Rho inhibition following either 
Eps8 or Rac1 knockdown restored motility (Figures 5B-E). This suggests that reduced 
motility following Eps8/Rac1 suppression is the result, at least in part, of an increase in 
Rho activation and not simply loss of Rac activity. As anticipated, TGF-β1 activation 
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assays showed the reverse effect; the increase in αvβ6-dependent TGF-β1 activation 
seen following Eps8/Rac1 siRNA knockdown was suppressed by Rho inhibition (Figures 
5F-G). Similarly, inhibition of basal levels of Rho activation induced cell migration and 
inhibited TGF-β1 activation (supplementary material, Figure S12). Our results show that 
the presence/absence of Eps8 signalling modulates different αvβ6-dependent functions, 
through differential regulation of Rho GTPases; Eps8 promotes Rac1 activation and cell 
motility, yet suppression of this signalling pathway leads to an increase in Rho activation, 
which promotes TGF-β1 activation.  
  
Differential effects of Eps8 on tumour-stromal interactions 
In Transwell® assays, the pro-migratory effect of Eps8 on cell invasion and migration 
was consistent across the different cell lines (Figure 2C), and independent of potential 
TGF-β1-dependent effects on cell movement. However, TGF-β1 also promotes 
myofibroblast transdifferention of stromal cells [38], therefore we examined the effect of 
Eps8 knockdown in 3D organotypic models containing fibroblasts or stellate cells. 
Surprisingly, we observed a differential effect of Eps8 on PDAC cell invasion; Eps8 
suppression significantly reduced organotypic invasion of BxPC3 cells, but promoted 
invasion of Panc0403 cells (Figure 6A; supplementary material, Figure S13). A similar 
effect was observed following Rac1- and Sos1-siRNA knockdown (supplementary 
material, Figure S14). TGF-β1 activation may promote invasion through modulating 
stromal myofibroblast differentiation [38], and notably, immunohistochemical analysis 
highlighted a distinctive subepithelial layer of αSMA-positive (activated) myofibroblasts 
in Panc0403 organotypic cultures (Figure 6B) that was not present in BxPC3 cultures. 
This desmoplastic reaction was enhanced following downregulation of Eps8 and 
revealed a clear interaction between αSMA-positive fibroblasts and invading tumour 
islands. Treatment of HFFF2 fibroblasts with hrTGF-β1 drives their differentiation from 
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fibroblasts to contractile, αSMA-positive myofibroblasts (Figure 6D); however, while both 
BxPC3 and Panc0403 cells activate TGF-β1, direct comparison revealed that levels of 
activation were significantly higher in Panc0403 cells (Figure 6C), possibly explaining 
the desmoplastic reaction in organotypic cultures with this cell line. Consistent with this, 
co-culture experiments of HFFF2 fibroblasts with Eps8 knockdown Panc0403 cells 
showed significantly increased myofibroblast differentiation (Figure 6E). Thus, although 
Eps8 knockdown suppresses both Panc0403 and BxPC3 motility in Transwell® assays, 
the increased stromal response induced by the Panc0403 cells is sufficient to over-ride 





Overexpression of αvβ6 is prognostic in various cancers [30, 39-40]; αvβ6 
signalling promotes tumour invasion through different mechanisms, regulating protease 
expression, and also activating the cytokine TGF-β1, which promotes tumour cell EMT 
and stromal myofibroblast differentiation [41]. Several studies suggest that αvβ6 
targeting may be an attractive therapeutic option; targeting αvβ6 in pre-clinical breast 
cancer models using a monoclonal antibody 264RAD, either alone or in combination 
with the HER2 inhibitor trastuzumab, resulted in significant inhibition of disease 
progression [9, 42]. However, targeting αvβ6 in human disease is complicated by its role 
in TGF-β1 activation, which may act as a tumour suppressor through effects on cell 
cycle regulators [43]. This has led to suggestions that αvβ6 should not be targeted in 
tumours retaining canonical TGF-β1 signalling. For example, blockade of TGF-β1 or 
αvβ6 in a genetically engineered KRAS PDAC mouse model was found to accelerate 
disease progression in Smad4-expressing tumours [15]. However, in tumours with 
homozygous deletion of SMAD4 the tumour suppressive effect of αvβ6 was lost [15]. 
These data highlight the need to dissect the molecular mechanisms regulating functions 
of this integrin. 
While αvβ6 has been shown to promote motility and TGF-β1 activation in a 
number of tumour types, no study has yet examined how these functions are linked. Our 
previous work in oral squamous cell carcinoma showed that Eps8 regulates integrin-
mediated invasion [30], and we therefore examined more broadly the role of Eps8 in 
regulating αvβ6-dependent functions. PDAC has been reported to overexpress both 
αvβ6 and Eps8, [7, 23], and consistent with these studies, we found that around 70% of 
tumours expressed αvβ6 and Eps8 at moderate/high levels (Figure 1A & 2A). Similar to 
other cancer types, we found that αvβ6 promotes cancer cell motility and TGF-β1 
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activation [38, 44-45], with suppression of αvβ6 resulting in complete inhibition of these 
processes.  
Eps8 has been shown previously to promote migration of PDAC cells [23]. We 
found that this motility-promoting effect appears to be through modulating activation of 
Rac1 via the Rac1-GEF Sos1, as we found that suppression of Eps8, Sos1 or Rac1 
independently inhibited PDAC migration/invasion. It is therefore probable that Eps8 
regulates αvβ6-dependent motility through the Eps8/Abi1/Sos1 tricomplex, although 
notably Eps8/Sos1 has also been shown to complex with CIIA, a protein associated with 
regulation of EMT and cell migration, to promote Rac1 activation independent of Abi1 
[46]. Notably, the inhibitory effect of Eps8 knockdown on cell motility resulted from 
differential regulation of Rac1 and RhoA activation (Figure 5); reduced migration 
following Eps8/Rac1 inhibition could be restored either by expressing constitutively 
active Rac1 or inhibiting Rho signalling. Rac1 has previously been reported to 
antagonise Rho activity directly [36], and regulate β1 integrin-dependent motility in 
PDAC and colon cancer cells [47-48]. A recent study using computational modelling also 
identified a MEK-driven feedback loop where inhibition of Eps8/Abi1/Sos1-mediatied 
Rac1 activation following Eps8 knockdown leads to increased Rho activation [49]. 
Unexpectedly, PDAC cells remained motile following inhibition of both Rac1 and Rho; 
several studies have similarly found that cell migration is possible in the absence of both 
GTPases [50-52].  
Notably, Eps8 acted as a negative regulator of αvβ6-dependent TGF-β1 
activation through the same mechanism (Figure 3), and both Rac1/Sos1 knockdown 
similarly induced TGF-β1 activation (Figure 5; supplementary material, Figure S8). The 
role of Rho kinases in αvβ6-dependent TGF-β activation has been implicated in several 
studies using ROCK inhibitors [11, 34-35]. It has also been hypothesised that increased 
cell tension generated by Rho activation results in a conformational change in LAP and 
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exposure of active TGF-β1 [13]. Our findings support this precept, and to the best of our 
knowledge this is the first study to provide a direct link between Rac1/Rho activity and 
αvβ6-dependent TGF-β activation, showing that cells can apply mechanical forces to 
LAP, and that the balance between Rac1/Rho GTPase activation favours different αvβ6-
dependent cell functions. 
Our results from 3D organotypic cultures highlight the problems of studying 
tumour cell motility in isolation, and stress the important role of stromal cells in the 
invasive process. In Transwell® assays Eps8 knockdown consistently suppressed PDAC 
motility; however, Eps8 knockdown in organotypic culture promoted invasion of 
Panc0403 cells. This was modulated through increasing TGF-β1 activation, which 
induced myofibroblastic transdifferentiation of fibroblasts/stellate cells (Figure 6; 
supplementary material, Figure S13). Rac1 or Sos1 knockdown produced a similar 
effect (supplementary material, Figure S14). This demonstrates how TGF-β1 activation 
can indirectly promote invasion through stromal regulation. Given the notion that αvβ6-
targeting should be avoided in tumours that retain canonical signalling, it is noteworthy 
that αvβ6 inhibition significantly suppressed invasion of Panc0403 cells that retain wild-
type SMAD4.  
In summary, αvβ6 is a promising target for tumour therapy, but given its different 
functional effects, a detailed knowledge of the underlying molecular mechanisms 
regulating these processes is required. We show that the balance in activation of Rho 
and Rac1 biases function towards TGF-β1 activation or motility respectively, with the 
presence or absence of Eps8 acting as a molecular switch that alters the balance of 
GTPase activation within the cell. In late stage disease, both αvβ6-dependent functions 
are likely to be tumour promoting; however, we can speculate that in premalignant 
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disease the bias towards an Eps8-expressing, invasive phenotype may help promote 
malignant transformation.  
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Figure Legends   
Figure 1. αvβ6 integrin is overexpressed in PDAC and promotes motility and TGF-
β activation (A) Representative images of immunohistochemistry staining of αvβ6 in 
PDAC (ii; tumour) and surrounding (i; uninvolved) tissue. Table, showing the staining 
intensity using the QuickScore method. (B) Western blot showing β6 expression in 
PDAC cell lines. The human oral squamous cell carcinoma cell line, VB6 was used as 
positive control. Equal loading was confirmed by HSC70. (C) Transwell® migration 
towards LAP and (D) Matrigel invasion of αvβ6-positive PDAC cells in the presence or 
absence of the αvβ6 blocking antibody, 63G9. Diagrams represent mean number of 
migrating/invading cells/well expressed as % of Ctl (BSA) +/- SD. n=3 (migration); n=4 
(invasion), *p<0.05; **p<0.01; ***p<0.001. (E) PDAC cells induce activation of TGF-β1 in 
an MLEC TGF-β activation assay, which is inhibited by 63G9. Diagram represents mean 
Relative Light Units expressed as % of MLEC +/- SD. n=6, ****p<0.0001. (F) Cytokeratin 
staining of organotypic gels showing invasion of non-targeting (Ctl) or β6 siRNA-
transfected BxPC3 and Panc0403 cells in the presence of HFFF2 fibroblasts and 
Primary pancreatic stellate cells (PPSC). Representative images are shown. 
Arrowheads pointing at invading tumour islands. Note reduced invasion depth in 
organotypic cultures with β6 siRNA-transfected cells. Diagrams showing mean invasion 
depth of three independent sections analysed by Image J software expressed as % of 
Ctl +/- SD, n=3, *p<0.05; **p<0.01; ***p<0.001. Western blots confirm downregulation of 
β6. Equal loading was confirmed by HSC70. Numbers below blots indicate the 
densitometry values measured using Image J normalised to HSC70 and expressed as a 
ratio to Ctl. 
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Figure 2. Eps8 is overexpressed in PDAC, promotes motility but inhibits TGF-β 
activation (A) Representative images of immunohistochemistry staining of Eps8 in 
PDAC (ii; tumour) and surrounding (i; uninvolved) tissue. Table showing the staining 
intensity using the QuickScore method. (B) Western blot showing Eps8 expression in 
five PDAC cell lines. The human oral squamous cell carcinoma cell line, VB6 was used 
as positive control. Equal loading was confirmed by HSC70. (C) Transwell® migration 
towards LAP and (D) Matrigel invasion of αvβ6-positive PDAC cells following Eps8 
knockdown in the presence or absence of the αvβ6 blocking antibody, 63G9. Diagram 
represents mean number of migrating/invading cells/well expressed as % of Ctl (BSA) 
+/- SD, n=3 (migration); n=4 (invasion), *p<0.05; ***p<0.001; ****p<0.0001. (E) TGF-β1 
activation by PDAC cells following Eps8 knockdown measured by an MLEC TGF-β 
activation assay, in the presence or absence of the αvβ6 blocking antibody, 63G9. 
Diagram represents mean Relative Light Units expressed as % of MLEC +/- SD, n=6, 
***p<0.001; ****p<0.0001. Western blots in C-E confirm downregulation of Eps8. Equal 
loading was confirmed by HSC70. Numbers below blots indicate the densitometry 
values measured using Image J normalised to HSC70 and expressed as a ratio to Ctl. 
 
Figure 3. Eps8 promoted Rac1 activation induces PDAC cell motility and inhibits 
TGF-β activation (A) Results of a GST-pull-down assay using GST-PAK-CRIB-coated 
sepharose beads showing EGF-induced Rac1 activation in PDAC cells transfected with 
non-targeting (Ctl) or Eps8 siRNA. Eps8 knockdown in the same lysates was confirmed 
on separate Western blots. (B) Transwell® migration of PDAC cells transfected with non-
targeting (Ctl) or Eps8 siRNA towards LAP. Diagram represents mean number of 
migrating cells/well expressed as % of Ctl (BSA) +/- SD, n=3, *p<0.05; **p<0.01; 
***p<0.001. (C) Overexpression of the constitutively active mutant of Rac1 (RacV12) 
restores migration of PDAC cell lines compared with empty vector control (EV) following 
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Eps8 knockdown. Diagram represents mean number of migrating cells/well expressed 
as % of EV (BSA) +/- SD, n=3, *p<0.05; **p<0.01; ***p<0.001. (D) Matrigel invasion of 
PDAC cells was significantly inhibited by Rac1 knockdown. Diagram represents mean 
number of invading cells/well expressed as % of Ctl +/- SD, n=4, **p<0.01; ***p<0.001. 
(E) Rac1 knockdown induces activation of TGF-β1 compared with non-targeting (Ctl) 
siRNA-transfected cells in an MLEC TGF-β activation assay. Rac1-induced TGF-β1 
activation was inhibited by the αvβ6 blocking antibody, 63G9. Diagram represents mean 
Relative Light Units expressed as % of MLEC +/- SD (Capan1/BxPC3 plotted on left, 
Panc0403 plotted on right Y-axis), n=6, *p<0.05; ****p<0.0001. Western blots in B-E 
confirm downregulation of Rac1. Equal loading was confirmed by HSC70. Numbers 
below blots indicate the densitometry values measured using Image J normalised to 
HSC70 and expressed as a ratio to Ctl. 
 
Figure 4. Inhibition of Eps8 promotes stress-fibre formation and force application 
on LAP (A) PDAC cells were transfected with either non-targeting (Ctl) or Eps8 siRNA, 
plated on 0.5 µg/ml LAP-coated coverslips and after an overnight incubation stained with 
Phalloidin-FITC (red) to visualize stress-fibre formation. DAPI (blue) was used as 
nuclear counter-stain. Cells were visualised using X100 optical zoom. Exposure of 
images was uniformly enhanced across images to aid better visibility. Actin stress-fibre 
formation was quantified in randomly selected fully spread cells using ImageJ. Cells 
were selected as regions of interest (ROIs) and Phalloidin mean fluorescence intensity 
was quantified within the identified ROIs. Diagram represents Mean relative 
fluorescence intensity / field expressed as % of Ctl +/- SD. n=10 fields/condition, 
*p<0.05; **p<0.01; ***p<0.001. Western blots confirm downregulation of Eps8 or Rac1 
following siRNA transfection. Equal loading was confirmed by HSC70. Numbers below 
blots indicate the densitometry values measured using ImageJ normalised to HSC70 
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and expressed as a ratio of Ctl. (B) Cell-mediated forces applied to 0.5 µg/ml LAP-
coated substrates, by BxPC3 cells transfected with non-targeting (Ctl) or Eps8-targeting 
(Eps8) siRNA, measured by traction force microscopy on hydrogels with predicted 
elastic moduli of 0.4 kPa (i - ii) and 12.5 kPa (iv - v). Data are represented as 
interrogation window force vectors (i and iv) and force magnitude maps (ii and v) for 
individual cells, and graphs (iii) showing mean traction force magnitude per field ± SEM; 
n = 12–20 fields/condition, **p<0.01; ***p<0.001. Data show a representative experiment 
of three independent repeats. 
 
Figure 5. Eps8 and Rac1 regulate PDAC cell motility and TGF-β activation by 
modulating RhoA (A) PDAC cells were transfected with non-targeting (Ctl) or Eps8-
targeting siRNA and RhoA activation was measured using a colorimetric G-LISA assay 
48h post-transfection. Diagrams represent mean active RhoA levels normalised to total 
RhoA levels expressed as % of Ctl +/- SD, n=3, **p<0.01; ns = non-significant. (B-C) 
Transwell® migration and (D-E) Matrigel invasion of PDAC cells transfected with non-
targeting (Ctl) or Eps8- (B-D) or Rac1- (C-E) targeting siRNA was measured following 
pre-treatment with vehicle control or 0.5 µg/ml CT04 Rho inhibitor (Rhoi). Diagrams 
represent mean number of migrating/invading cells/well expressed as % of Ctl (BSA) +/- 
SD, n=3 (migration); n=4 (invasion), *p<0.05; **p<0.01; ***p<0.001; ns = non-significant. 
(F-G) PDAC cells transfected with non-targeting (Ctl) and Eps8- (F) or Rac1- (G) 
targeting siRNA were pre-treated with vehicle control or 0.5 µg/ml CT04 Rho inhibitor 
(Rhoi) after which they were plated on top of MLEC cells in the absence of the inhibitor. 
Diagrams represent mean Relative Light Units expressed as % of MLEC +/- SD, n=6, 
**p<0.01; ***p<0.001; ****p<0.0001. Western blots confirm downregulation of Eps8 (A, B, 
D, F) and Rac1 (C, E, G). Equal loading was confirmed by HSC70. Numbers below blots 
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indicate the densitometry values measured using ImageJ normalised to HSC70 and 
expressed as a ratio to Ctl. 
 
Figure 6. Differential activation of stromal cells by PDAC cell lines (A-B) BxPC3 
and Panc0403 cells were transfected with either non-targeting (Ctl) or Eps8-targeting 
siRNA and organotypic invasion assays were performed in the presence of HFFF2 
fibroblasts over a period of 12 days. A representative image of cytokeratin- (Ai) or the 
myofibroblast marker αSmooth muscle actin- (αSMA; Bi) stained section is shown. 
Arrowheads in (Bi) point at interaction between invading tumour islands and activated 
fibroblasts. (Aii) Diagram showing relative mean invasion depth of three independent 
sections analysed by Image J software expressed as % of Ctl +/- SD, **p<0.01. (Bii) 
Diagram represent αSMA-positive area expressed as % of Ctl +/-SD analysed by the 
Trainable Weka segmentation plugin in the Image J software, n=7, ****p<0.0001; ns = 
non-significant. Western blots confirm downregulation of Eps8. Equal loading was 
confirmed by HSC70. Numbers below blots indicate the densitometry values measured 
using Image J normalised to HSC70 and expressed as a ratio of Ctl. (C) TGF-β1 
activation by BxPC3 and Panc0403 cells was measured by the MLEC TGF-β activation 
assay and showed increased TGF-β1 activation by Panc0403 cells. Diagram show the 
results of seven independent experiments and represents mean Relative Light Units 
expressed as % of MLEC +/- SEM, **p<0.01. (Di) HFFF2 fibroblasts were treated or not 
with hrTGF-β1 for 48 h and αSMA-positive stress-fibres (green) were visualised by 
confocal microscopy. DAPI (blue) was used as nuclear counterstain. Stress-fibre 
formation was quantified in randomly selected fields using ImageJ. Diagram represents 
Mean relative fluorescence intensity / field expressed as % of Ctl +/- SD. n=6 
fields/condition, ****p<0.0001. (Dii) TGF-β1-induced αSMA expression was confirmed 
using Western blotting. (E) Panc0403 cells were transfected with non-targeting (Ctl) or 
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Eps8-targeting siRNA and were plated on top of HFFF2 fibroblasts for 72 h. Stress-fibre 
formation in the fibroblasts was detected by staining for αSMA (green); cancer cells 
were identified by cytokeratin staining (red) using confocal microscopy. DAPI (blue) was 
used as nuclear counterstain. Stress-fibre formation was quantified in randomly selected 
fields using ImageJ. Diagram represents Mean relative fluorescence intensity / field 
expressed as % of Ctl +/- SD. n=6 fields/condition; **p<0.01. Western blots in Aii and E 
confirm downregulation of Eps8. Equal loading was confirmed by HSC70. Numbers 
below blots indicate the densitometry values measured using ImageJ normalised to 
HSC70 and expressed as a ratio of Ctl. Data show a representative experiment of at 
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Supplementary materials and methods  
 
Reverse transcription and real-time PCR 
Cells were transfected with Eps8 siRNA using Oligofectamine™ transfection reagent and 
24, 48 or 72 h post-transfection cells were harvested and either lysed in NP40 lysis buffer 
to extract protein or processed using the RNEasy mini kit (Qiagen, Hilden, Germany) to 
isolate total RNA. An aliquot of 500 ng total RNA was reverse transcribed to synthesize 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA), as per the manufacturer’s instructions. Real-time PCR using Power 
SyBr® Green (Life Technologies, Carlsbad, CA, USA) was performed with the 7500 Real-
time PCR system (Applied Biosystems). The expression of the EPS8 gene (Forward 
Primer-CGACCAAGGGACTTTGAGA, Reverse Primer- GCACATCTCTGTCAATGCGG) 
relative to the reference gene, GAPDH (Forward Primer-AGCAATGCCTGCACCACCAAC, 
Reverse Primer-CCGGAGGGGCCATCCACAGTCT) was calculated using the ∆∆Ct 
method. 
 
Transfection with Eps8-EGFP 
Cells were plated at a density of 300 000 cells/well in 6-well plates overnight and 
transfected with either 3 µg empty vector control (pEGFP-C2) or EGFP-tagged mouse 
Eps8 using Fugene HD transfection reagent (Promega) and 24 h post-transfection cells 
were used for either Transwell® migration or MLEC TGF-β activation assays.  
 
FACS analysis 
Cell surface expression of the αvβ6 integrin was quantified by flow cytometry. Total and 
active cell surface levels of integrins were detected using 620w and 6.2G2 antibodies 
(Biogen Idec Inc, Cambridge, MA, USA) for 1 h at 4 °C followed with incubation with 
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Alexa-488 conjugated secondary antibodies (Invitrogen) for 45 min at 4 °C in the dark. 
Labelled cells were scanned on FACS Canto II cytometer (BD Biosciences, San Diego, 




Cells were transfected with non-targeted or Eps8-targeting siRNA for 48 h and were pre-
treated or not with the αvβ6 blocking antibody 63G9 (Biogen Idec) for 30 min at 4 °C and 
plated on TGF-β1 LAP-coated 96-well plates in quadruplicates. After one hour incubation 
at 37 °C cells were fixed in 1% glutaraldehyde (Sigma-Aldrich, Gillingham, Dorset, UK) 
and stained with crystal violet. Stained cells were washed with PBS and the remaining 
crystal violet was dissolved in 50% acetic acid. Absorbance was determined using a 
Varioskan plate reader at 540 nm. 
 
Supplementary Table S1. Antibodies used in the study. N/A – not applicable 
Primary antibody Species Catalogue/Clone 
number 
Supplier IHC/IF dilution WB/FACS/Blocking 
concentration 
HSC70 Mouse sc-7298 / B-6 Santa Cruz Biotechnology 
(Dallas, TX, USA) 
N/A 1:10 000 
6.3G9 (β6) 
Blocking 
Mouse [26] / 25-3-1 Biogen Idec 
(Cambridge, MA, USA) 
N/A 10 µg/ml for blocking 
6.20w (β6) Rat N/A / N/A In-house N/A 1:500 / 20 µg/ml / N/A 
62G2 (β6) Mouse [26] / 87-1 Biogen Idec 
(Cambridge, MA, USA) 
2 µg/ml / N/A N/A / 10 µg/ml / N/A 
αV Rabbit 4711 / N/A Cell Signaling Technology 
(Danvers, MA, USA) 
N/A 1:1000 / N/A / N/A 
Eps8 Mouse 610144 / 15 BD Biosciences  
(Franklin Lakes, NJ, USA) 
1:400 / 1:100 1:2 000 / N/A / N/A 
Rac1 Mouse 05-389 / 23A8 Millipore 
(Watford, UK) 
N/A 1:1 000 / N/A / N/A 
Primary antibody Species Catalogue/Clone 
number 
Supplier IHC/IF dilution WB/FACS/Blocking 
concentration 
Rac1 Mouse ARC03 / N/A Cytoskeleton 
(Denver, CO, USA) 
N/A /  
25 µg/ml 
N/A 
Sos1 Rabbit sc-17793 / A-9 Santa Cruz Biotechnology 
(Dallas, TX, USA) 
1:400 / N/A 1:1 000 / N/A / N/A 
αSMA Mouse M0851 / 1A4 Dako 
(Ely, UK) 
1:250 / 1:100 N/A 
αSMA Mouse A2547 / 1A4 Sigma-Aldrich 
(Gillingham, UK) 
N/A 1:1 000 / N/A / N/A 
Cytokeratin Mouse IR053 / AE1/AE3 Dako 
(Ely, UK) 
1:100 / N/A N/A 
Cytokeratin Rabbit Z0622 / N/A Dako 
(Ely, UK) 
N/A / 1:500 N/A 
EGFR Goat AF231 / N/A R&D Systems 
(Minneapolis, MN, USA) 
N/A 1:1000 / N/A / N/A 
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Supplementary Table S2. siRNAs used in the study 












AM16706 30 nM 
Hs_EPS8_1 TCGGTTCTAAAG
GATGATATT 
Qiagen SI00380737 30 nM 
Hs_EPS8_2 TTGGATATTGTG
AGACCTCCA 
Qiagen SI00380744 30 nM 
Hs_EPS8_3 CAGGTGGATGTT
AGAAGTCGA 














Supplementary Figure Legends  
 
Figure S1. Optimisation of siRNA sequences. BxPC3 cells were transfected with 30, 50 
or 100 nM Eps8 (A-B), Rac1 (C) and Sos1 (D) siRNA and cells were harvested 24, 48 or 
72 h post-transfection and protein (A, C, D) or mRNA (B) levels were tested using Western 
blotting (A, C, D) or Reverse Transcription - quantitative PCR and expressed as fold 
change relative to Ctl. GAPDH was used as a reference transcript. (B). Results confirmed 
that the siRNA sequences produce significant downregulation of the proteins at each time 
point relevant to our functional assays. Equal loading on Western blots was confirmed by 
HSC70. Numbers below blots indicate the densitometry values measured using ImageJ 
normalised to HSC70 and expressed as a ratio of Ctl.  
 
Figure S2. αvβ6 inhibition does not affect PDAC cell migration towards BSA. (A) 
Western blot showing αv expression in PDAC cell lines. Equal loading was confirmed by 
HSC70. (B) 50 000 PDAC cells were pre-treated with 10 µg/ml of the αvβ6 blocking 
antibody 63G9 for 30 min before plating them into the top well of bovine serum albumin-
coated Transwell® migration inserts. The number of cells migrated to the bottom wells was 
counted after an overnight incubation and no change in the number of migrating cells was 
detected upon pre-treatment with the blocking antibody. Note the low number of migrating 
cells. Diagram represents mean number of migrating cells/well +/- SD; n=3.  
 
Figure S3. αvβ6-positive PDAC cells activate TGF-β1. PDAC cells (120 000) were 
plated on top of MLEC cells and TGF-β1 activation was measured after an overnight 
incubation. The αvβ6-positive Capan1, BxPC3 and Panc0403 cancer cells induced 
significant activation of TGF-β1, while αvβ6-negative SW1990 and SU86.86 cells did not. 
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Diagram represents Relative Light Units expressed as % of Ctl +/- SD, n=6, * p<0.05; *** 
p<0.001; **** p<0.001; ns = non-significant.    
 
Figure S4. Eps8 knockdown using four siRNA sequences inhibits PDAC cell 
migration and induces TGF-β1 activation. (A) Transwell® migration of BxPC3 cells 
towards LAP was significantly inhibited by transfection with the Eps8 siRNA sequence 
used throughout the study (Eps8) and three alternative siRNA sequences targeting Eps8 
(♯1-2-3). Diagram represents mean number of migrating cells/well expressed as % of Ctl 
(BSA) +/- SD, n=3, * p<0.05. (B) Eps8 knockdown using four individual siRNA sequences 
induces activation of TGF-β1 in BxPC3 cells measured by an MLEC TGF-β activation 
assay. Diagram represents mean Relative Light Units expressed as % of Ctl +/- SD, n=6, 
** p<0.01; ***p<0.001; ****p<0.0001. Western blots confirm downregulation of Eps8 using 
RNA interference. Equal loading was confirmed by HSC70. Numbers below blots indicate 
the densitometry values measured using ImageJ normalised to HSC70 and expressed as 
a ratio to Ctl. 
 
Figure S5. Eps8 overexpression increases cell motility while inhibits TGF-β 
activation. (A) Capan1, BxPC3 and Panc0403 cells were transfected with empty vector 
(EV) or Eps8-EGFP 24 h before plating them into a Transwell® migration assay. Eps8 
overexpression in all three cell lines significantly increased cell migration towards the αvβ6 
ligand, LAP. Diagram represents mean number of migrating cells/well expressed as % of 
Ctl (BSA) +/- SD (Capan1/Panc0403 plotted on left, BxPC3 plotted on right Y-axis), n=3, * 
p<0.05; ***p<0.001. (B) Capan1, BxPC3 and Panc0403 cells were transfected with empty 
vector (EV) or Eps8-EGFP 24 h before plating them on top of MLEC cells. Eps8 
overexpression significantly inhibited TGF-β activation in all three cell lines. Diagram 
represents mean Relative Light Units expressed as % of MLEC +/- SD (Capan1/Panc0403 
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plotted on left, BxPC3 plotted on right Y-axis), n=6, ** p<0.01; ****p<0.0001. (C) Eps8-
EGFP expression was confirmed by Western blotting. HSC70 was used as loading control. 
 
Figure S6. Eps8 does not affect cell surface levels of β6 integrin. Cells were 
transfected with non-targeting (Ctl) or Eps8-targeting siRNA and cell surface levels of total 
(A) or active (B) β6 integrin were measured by FACS analysis 48 h post-transfection using 
either anti-β6 (620W) (A) or anti-active β6 (6.2G2) antibodies (B). Diagrams represent 
Mean Fluorescence Intensity expressed as % of Ctl +/- SD, n=3, ns = non-significant. (C) 
Cells were transfected with either non-targeting (Ctl) or Eps8-targeting siRNA and cell 
adhesion on LAP was measured 48 h post-transfection. Eps8 downregulation had no 
effect on αvβ6-specific adhesion of PDAC cells. Diagrams represent absorbance at 540 
nm expressed as % of Ctl (BSA) +/- SD, n=4, ns = non-significant. Western blots 
confirmed downregulation of Eps8 following siRNA transfection. Equal loading was 
confirmed by HSC70. Numbers below blots indicate the densitometry values measured 
using ImageJ normalised to HSC70 and expressed as a ratio to Ctl.   
 
Figure S7. EGF stimulation potentiates αvβ6 signalling and function. (A) Western blot 
showing expression of EGFR in the αvβ6-positive Capan1, BxPC3 and Panc0403 cancer 
cells. The SCC25 oral squamous cell carcinoma cell line was used as positive control. 
Equal loading was confirmed by HSC70. (B) Stimulation of Capan1, BxPC3 and Panc0403 
cells with 20 ng/ml EGF induced a significant increase in migration levels towards the αvβ6 
integrin ligand LAP. This EGF-induced migration was completely inhibited by the αvβ6 
blocking antibody 63G9 confirming that EGF-induced migration of PDAC cells was αvβ6-
dependent. Diagram represents mean number of migrating cells/well expressed as % of 
BSA +/- SD, n=3, * p<0.05; ** p<0.01; ***p<0.001 ****p<0.0001. (C) Stimulation of 
Capan1, BxPC3 and Panc0403 cells with 20 ng/ml EGF induced a significant activation of 
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the small GTPase Rac1 as evidenced by a GST-PAK1-CRIB pull-down assay. Knockdown 
of αvβ6 completely blocked EGF-induced Rac1 activation in all cell lines confirming αvβ6 
dependency. β6 knockdown in the same lysates was confirmed on separate Western 
blots. Equal loading was confirmed by HSC70. Numbers below blots indicate the 
densitometry values measured using ImageJ normalised to HSC70 and expressed as a 
ratio to Ctl.     
 
Figure S8. Sos1 is overexpressed in PDAC, promotes motility but inhibits TGF-β 
activation. (A) A representative image of immunohistochemical staining of Sos1 in PDAC 
(ii; tumour) and surrounding (i; uninvolved) tissue. Table showing the staining intensity 
using the QuickScore method. (B) Western blot showing Sos1 expression in three αvβ6-
positive PDAC cell lines. The human oral squamous cell carcinoma cell line, VB6 was 
used as positive control. Equal loading was confirmed by HSC70. (C) Results of a GST-
pull-down assay using GST-PAK1-CRIB-coated Sepharose beads showing that Sos1 
knockdown completely inhibits EGF-induced Rac1 activation compared to cells transfected 
with non-targeting (Ctl) siRNA in Capan1, BxPC3 and Panc0403 cells. Western blot for 
Capan1 cells originated from the same experiment presented in Figure 3A. Eps8 and Sos1 
knockdown in the same lysates was confirmed on separate Western blots. Equal loading 
was confirmed by HSC70. Numbers below blots indicate the densitometry values 
measured using ImageJ normalised to HSC70 and expressed as a ratio to Ctl. (D) Sos1 
downregulation by RNA interference significantly inhibits Transwell® migration of Capan1, 
BxPC3 and Panc0403 cells towards the αvβ6 integrin ligand, LAP compared to non-
targeting (Ctl) siRNA. Diagram represents mean number of migrated cells/well expressed 
as % of Ctl (LAP) +/- SD, n=3, * p<0.05; ** p<0.01. (E) Invasion of Capan1, BxPC3 and 
Panc0403 cells through Matrigel-coated Transwells® was significantly inhibited by 
downregulation of Sos1 using RNA interference. Diagram represents mean number of 
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invaded cells/well expressed as a % of Ctl +/- SD, n=4, * p<0.05; ** p<0.01; *** p<0.001. 
(F) Sos1 knockdown induced activation of TGF-β1 compared to non-targeting (Ctl) siRNA-
transfected cells in an MLEC TGF-β activation assay. Sos1-induced TGF-β activation was 
inhibited by the αvβ6 blocking antibody, 63G9. Diagram represents mean Relative Light 
Units expressed as % of MLEC +/- SD, (Capan1/BxPC3 plotted on left, Panc0403 plotted 
on right Y-axis), n=6, ** p<0.01; ***p<0.001; ****p<0.0001. Western blots in D-F confirmed 
downregulation of Sos1 using RNA interference. Equal loading was confirmed by HSC70. 
Numbers below blots indicate the densitometry values measured using ImageJ normalised 
to HSC70 and expressed as a ratio to Ctl.  
 
Figure S9. Eps8 and Rac1 regulate cell motility and TGF-β activation in the same 
pathway. (A) Transwell® migration of Capan1, BxPC3 and Panc0403 cells towards LAP is 
inhibited by overnight pre-treatment with 50 µM of the Rac1 inhibitor, NSC23766 (Raci). 
Diagram represents mean number of migrated cells/well expressed as % of Ctl (BSA) +/- 
SD, n=3, ** p<0.01; ***p<0.001. (B) Transwell® migration of Capan1 cells towards LAP 
was inhibited to the same extent by downregulation of Eps8 or Rac1 and simultaneous 
downregulation of both proteins. Diagram represents mean number of migrated cells/well 
expressed as % of Ctl (BSA) +/- SD, n=3, ** p<0.01; ***p<0.001. Western blots confirm 
downregulation of Eps8 and Rac1. Equal loading was confirmed by HSC70. Numbers 
below blots indicate the densitometry values for Eps8 (D.Eps8) and Rac1 (D.Rac1) 
knockdown measured using ImageJ normalised to HSC70 and expressed as a ratio to Ctl. 
(C) Capan1, BxPC3 and Panc0403 cells were pre-treated overnight by 50 µM of Rac1 
inhibitor, NSC23766 (Raci) after which they were plated on top of MLEC cells in the 
absence of the inhibitor. Rac1 inhibition significantly increased TGF-β activation in all three 
cell lines. Diagram represents mean Relative Light Units expressed as % of MLEC +/- SD, 
n=6, ** p<0.01; ***p<0.001; **** p<0.0001. (D) Eps8, Rac1 or Eps8 and Rac1 siRNA 
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induced significantly increased TGF-β activation in Capan1 cells. Diagram represents 
mean Relative Light Units expressed as a % of MLEC +/- SD, n=6, ** p<0.01; ***p<0.001. 
Western blots in (B) confirmed downregulation of Eps8 and Rac1 using RNA interference.  
 
Figure S10. Stress-fibre formation was reduced in cells with incomplete knockdown 
of Eps8 and Rac1. Capan1 cells were transfected with Eps8 or Rac1 siRNA, plated on 
0.5 µg/ml LAP-coated coverslips and after an overnight incubation stained with Phalloidin-
FITC (red) to visualize stress-fibre formation or anti-Eps8 or Rac1 antibodies (green) to 
detect the level of knockdown. DAPI (blue) was used as nuclear counter-stain. Cells with 
absent or very low levels of Eps8 (A, bottom panels) and Rac1 (B, bottom panels) 
expression showed increased stress-fibre formation, whereas cells in which Eps8 (A, top 
panels) and Rac1 (B, top panels) downregulation was incomplete did not produce stress-
fibres. Images were captured at the same microscope setting and exposure was uniformly 
enhanced across images to aid better visibility. Representative images are shown. 
Western blots confirm downregulation of Eps8 or Rac1 following siRNA transfection. Equal 
loading was confirmed by HSC70. Numbers below blots indicate the densitometry values 
measured using ImageJ normalised to HSC70 and expressed as a ratio to Ctl.  
 
Figure S11. The cell permeable Rho inhibitor CT04 inhibits stress-fibre formation in 
Eps8 knockdown cells. Capan1 cells transfected with Eps8 siRNA were plated on 0.5 
µg/ml LAP-coated coverslips in the presence of 1% serum until they have fully adhered 
and spread. Medium on the cells was changed to serum-free medium and cells were 
incubated in the absence (top panel) or presence (bottom panel) of 0.5 µg/ml CT04 Rho 
inhibitor. After overnight incubation cells were fixed and stained with Phalloidin-FITC (red) 
to visualize stress-fibre formation. DAPI (blue) was used as nuclear counterstain. 
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Exposure was uniformly enhanced across images to aid better visibility. A representative 
image is shown. 
 
Figure S12. Rho inhibition induces cell motility and inhibits TGF-β activation. (A) 
Capan1, BxPC3 and Panc0403 cells were pre-treated with 0.5 µg/ml of the CT04 Rho 
inhibitor (Rhoi) before plating them into a Transwell® migration assay. Migration towards 
LAP of all three cell lines was significantly increased by Rho inhibition. Diagram represents 
mean number of migrated cells/well expressed as a % of Ctl (BSA) +/- SD 
(Capan1/Panc0403 plotted on left, BxPC3 plotted on right Y-axis), n=3, * p<0.05; **p<0.01. 
(B) Capan1, BxPC3 and Panc0403 cells were pre-treated by 0.5 µg/ml of the CT04 Rho 
inhibitor (Rhoi) after which they were plated on top of MLEC cells in the absence of the 
inhibitor. Rho inhibition significantly inhibited TGF-β activation in all three cell lines. 
Diagram represents mean Relative Light Units expressed as a % of MLEC +/- SD (Capan1 
plotted on left, BxPC3/Panc0403 plotted on right Y-axis), n=6, ** p<0.01; ****p<0.0001.  
 
Figure S13. BxPC3 and Panc0403 cells invade differently in the presence of primary 
pancreatic stellate cells. BxPC3 and Panc0403 cells were transfected with either non-
targeting (Ctl) or Eps8-targeting siRNA and organotypic invasion assays were performed 
in the presence of primary pancreatic stellate cells over a period of 12 days. While 
invasion of BxPC3 cells was significantly inhibited by downregulation of Eps8 compared to 
Ctl cells, invasion of Panc0403 cells was significantly increased. A representative image of 
cytokeratin-stained sections is shown. Diagram shows mean invasion depth of three 
independent sections analysed by ImageJ software expressed as a % of Ctl +/- SD. n=3, * 
p<0.05; ** p<0.01.  
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Figure S14. Rac1 and Sos1 inhibits invasion of Panc0403 but not of BxPC3 cells. (Ai) 
BxPC3 and Panc0403 cells were transfected with either non-targeting (Ctl) or Rac1-
targeting siRNA and organotypic invasion assays were performed in the presence of 
HFFF2 fibroblasts over a period of 12 days. While downregulation of Rac1 inhibited 
invasion of BxPC3 cells compared to Ctl cells, it induced a significant level of invasion in 
Panc0403 cells. A representative image of cytokeratin-stained section is shown. (Aii) 
Diagrams show mean invasion depth of three independent sections analysed by ImageJ 
software expressed as % of Ctl +/- SD. n=3, ** p<0.01; *** p<0.001. Western blots 
confirmed downregulation of Rac1. Equal loading was confirmed by HSC70. (Bi) BxPC3 
and Panc0403 cells were transfected with either non-targeting (Ctl) or Sos1-targeting 
siRNA and organotypic invasion assays were performed in the presence of HFFF2 
fibroblasts over a period of 12 days. While downregulation of Sos1 inhibited invasion of 
BxPC3 cells compared to Ctl cells, it induced a significant level of invasion in Panc0403 
cells.  A representative image of cytokeratin-stained section is shown. (Bii) Diagrams show 
mean invasion depth of three independent sections analysed by ImageJ software 
expressed as a % of Ctl +/- SD. n=3, * p<0.05; ** p<0.01. Western blots confirmed 
downregulation of Sos1. Equal loading was confirmed by HSC70. Numbers below blots in 
(Aii) and (Bii) indicate the densitometry values measured using ImageJ normalised to 
HSC70 and expressed as a ratio to Ctl. 	














